Literature DB >> 11239882

Macular translocation for subfoveal choroidal neovascularization in angioid streaks.

D B Roth1, M Estafanous, H Lewis.   

Abstract

PURPOSE: To report a case of visual improvement after macular translocation performed for a subfoveal choroidal neovascular membrane in a patient with pseudoxanthoma elasticum and angioid streaks.
METHODS: The fovea was translocated inferiorly by scleral imbrication, intentional retinal detachment with a small posterior retinotomy, and partial fluid-air exchange. The choroidal neovascular membrane was photocoagulated 1 week later.
RESULTS: The visual acuity of the patient improved from 20/125 to 20/40. The center of the foveal avascular zone was moved inferiorly 844 microm. The choroidal neovascular membrane was extrafoveal after translocation and was treated with laser photocoagulation.
CONCLUSION: Macular translocation may be considered in the management of subfoveal choroidal neovascular membrane in patients with pseudoxanthoma elasticum and angioid streaks.

Entities:  

Mesh:

Year:  2001        PMID: 11239882     DOI: 10.1016/s0002-9394(00)00809-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  12 in total

Review 1.  [Pseudoxanthoma elasticum].

Authors:  M S Ladewig; C Götting; C Szliska; P C Issa; H-M Helb; I Bedenicki; H P N Scholl; F G Holz
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

2.  Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks.

Authors:  Heinrich Heimann; Faik Gelisken; Joachim Wachtlin; Andreas Wehner; Michael Völker; Michael H Foerster; Karl Ulrich Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-10       Impact factor: 3.117

Review 3.  Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations.

Authors:  N Chassaing; L Martin; P Calvas; M Le Bert; A Hovnanian
Journal:  J Med Genet       Date:  2005-05-13       Impact factor: 6.318

4.  Acute stroke after intravitreal bevacizumab to treat choroidal neovascularization due to angioid streaks in pseudoxanthoma elasticum : a severe systemic adverse event after an off-label procedure.

Authors:  Gianluca Besozzi; Andrea Ferrara; Enrico Epifani; Daniela Intini; Margherita Apruzzese; Antonio Provenzano; Michele Vetrugno
Journal:  Int Ophthalmol       Date:  2012-10-14       Impact factor: 2.031

Review 5.  Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms.

Authors:  Qiaoli Li; Qiujie Jiang; Ellen Pfendner; András Váradi; Jouni Uitto
Journal:  Exp Dermatol       Date:  2008-10-22       Impact factor: 3.960

6.  Macular translocation in a patient with adult-onset foveomacular vitelliform dystrophy with light- and electron-microscopic observations on the surgically removed subfoveal tissue.

Authors:  Claus Eckardt; Ute Eckardt; Stephanie Groos; Liliana Luciano; Enrico Reale
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-05-11       Impact factor: 3.117

7.  [Intraocular injections of bevacizumab in rare indications--two cases].

Authors:  T Wecke; C Knop; W Schreiber; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

8.  Loss of vision associated with angioid streaks in beta-thalassemia intermedia.

Authors:  Athanasios Aessopos; Charalampos S Floudas; Maria Kati; Maria Tsironi; Xanthoula Giakoumi; Charalampos Livir-Rallatos; Dimitrios Farmakis
Journal:  Int J Hematol       Date:  2007-12-11       Impact factor: 2.490

9.  Long-term follow-up of choroidal neovascularization secondary to angioid streaks: case series and literature review.

Authors:  Saba Al-Rashaed; J Fernando Arevalo
Journal:  Clin Ophthalmol       Date:  2012-07-05

10.  Angioid streaks, clinical course, complications, and current therapeutic management.

Authors:  Ilias Georgalas; Dimitris Papaconstantinou; Chrysanthi Koutsandrea; George Kalantzis; Dimitris Karagiannis; Gerasimos Georgopoulos; Ioannis Ladas
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.